Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Journal article
Lv X. et al, (2024), iScience, 27
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Journal article
Datoo MS. et al, (2024), Lancet (London, England), 403, 533 - 544
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Journal article
Schmit N. et al, (2024), The Lancet. Infectious diseases
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.
Journal article
Chong AY. et al, (2024), American journal of human genetics
Mexican Biobank advances population and medical genomics of diverse ancestries.
Journal article
Sohail M. et al, (2023), Nature
Injectable core-shell microspheres deliver prime-boost immunisation in a single shot
Preprint
Guyon R. et al, (2023)
Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms.
Journal article
Reinke S. et al, (2023), Cell reports. Medicine
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.
Journal article
Dold C. et al, (2023), Science translational medicine, 15
Higher antigen occupancy of high avidity CSP serum antibodies associates with protection against human malaria
Journal article
Li K. et al, (2023), Biophysical journal, 122, 144a - 145a
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Journal article
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
A tool for evaluating heterogeneity in avidity of polyclonal antibodies.
Journal article
Li K. et al, (2023), Frontiers in immunology, 14
Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso
Journal article
Morter R. et al, (2022), Frontiers in Immunology, 13
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.
Journal article
Datoo MS. et al, (2022), The Lancet. Infectious diseases, 22, 1728 - 1736
Immunopeptidomic Analysis of BoLA-I and BoLA-DR Presented Peptides from Theileria parva Infected Cells.
Journal article
Connelley T. et al, (2022), Vaccines, 10
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Journal article
Madhavan M. et al, (2022), eBioMedicine, 85, 104298 - 104298
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Journal article
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
Genome-wide association study of leprosy in Malawi and Mali.
Journal article
Gilchrist JJ. et al, (2022), PLoS pathogens, 18
STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.
Journal article
Padron-Regalado E. et al, (2022), Scientific reports, 12
BIRC6 modifies risk of invasive bacterial infection in Kenyan children.
Journal article
Gilchrist JJ. et al, (2022), eLife, 11